The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease A Perspective on Erythropoietin as a Potential Adjuvant Therapy Post date July 19, 2024 ← Thyroid Dysfution in acute cornory syndrome and its prognostic implications → Platelet glycogen synthase kinase 3β regulates plasma β amyloid and phosphorylated tau levels in chronic kidney disease patients with cognitive dysfunction; therapeutic role of erythropoietin